Overview
Global Pediatric Neurology Devices market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Pediatric neurology is addressed as a specialized component of treatment that deals with the detection and management of neurological disorders in neonates (newborns), infants, juveniles, and adolescents. Pediatric neurology devices are the instruments that are utilized to address neurological issues in youngsters. The technology employed in pediatric neurology devices is developed for curing neurological conditions.
Market Dynamics: Drivers & Restraints
Increase in Product Introductions
The increase in pediatric neurological device introductions into the market is expected to boost the global market growth during the forecast period. For instance, in July 2023, Nicklaus Children’s Hospital introduced a new high-density electroencephalogram (HD EEG) system and transcranial magnetic stimulation (TMS) machine, evolving as one of the foremost in the country to deliver this equipment for the care of pediatric individuals.
Moreover, in October 2022, NeuroSigma introduced the Monarch eTNS System for treating pediatric attention-deficit/hyperactivity disorder (ADHD) and the Pediatric Care Copay program to promote patient access to the development. Furthermore, growing technological advancements, growing awareness and cases among other factors are also expected to contribute to the global market growth during the forecast period.
High Device Cost
The high cost of neurology devices is expected to hamper the global market growth during the forecast period. For instance, Vagus nerve stimulation (VNS) therapy is an established method for treating patients with refractory seizures, while the initial cost of the device is about 10,000 US dollars which again requires regular battery changes adding to the overall cost, slowing the global market growth. Furthermore, the lack of professional specialists and high product development costs among other additional factors are slowing the global market growth in the forecast period.

Segment Analysis
The global pediatric neurology devices market is segmented based on product type, indication, age group, end user and region.
Nerve Simulation Product Type is Expected to Dominate Market
Owing to the increase in new product introductions into the segment the nerve simulation product type is expected to hold the majority of the global market share during the forecast period. For instance, in February 2021, the FDA awarded 510(k) authorization to electroCore to extend the authorization of gammaCore, the corporation’s non-invasive vagus nerve stimulation, for the acute and preventative therapy of adolescent migraine. Moreover, in February 2023, LivaNova PLC, a top medical technology and innovation corporation, introduced SenTiva DUO, an implantable pulse generator (IPG) with a dual-pin header to deliver VNS Therapy in the treatment of drug-resistant epilepsy.

Geographical Analysis
North America is Expected to Dominate the Global Market
Owing to the increase in pediatric neurology device market developments in North America the region is expected to dominate the global market during the forecast period. For instance, in October 2022, NeuroSigma, Inc., a Los Angeles-based bioelectronics corporation, introduced the Monarch eTNS System the foremost medical device authorized by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD for pediatric patients (i.e., children ages 7-12), at the annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Toronto.
Also, in December 2022, Brain Scientific, a Florida-based applied science technology corporation, formed a new distribution agreement with MVAP Medical Supplies to push sales into the rapidly expanding and underserved pediatric EEG marketplace.
Further, in January 2023, NeuroSigma, Inc., a Los Angeles-based bioelectronics corporation trading external trigeminal nerve stimulation (eTNS) technology for the treatment of neurological and neuropsychiatric disorders, began a strategic digital marketing collaboration with Data360, a top provider of targeted, online marketing for the healthcare industry.

COVID-19 Impact Analysis
Various neurological manifestations have been associated with children’s SARS-CoV-2 infection. It was crucial to identify and provide them with appropriate and timely treatment because they can be potentially serious and life-threatening, and some can lead to long-lasting consequences.
Different neuro-pathophysiological mechanisms were presented, but a causal relationship between SARS-CoV-2 infection and neurological manifestations stays unproven. COVID-19 affects patients with neurological diseases especially, not only by the disease itself but also by its complications and pandemic management measures, which has impacted the gbal market in a mixed way.
Market Segmentation
By Product Type

  • Neurostimulation Devices
  • Neurosurgery Devices
  • Interventional Devices
  • CSF Management Devices
  • Other Product Types


By Indication

  • Seizure
  • Stroke
  • Hydrocephalus
  • Neurooncological Indications
  • Other Indications


By Age Group

  • 0-5 Years
  • 5-10 Years
  • 10-15 Years


By End User

  • Hospital
  • Specialty Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Others


By Region

  • North America


o U.S.
o Canada
o Mexico

  • Europe


o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe

  • South America


o Brazil
o Argentina
o Rest of South America

  • Asia-Pacific


o China
o India
o Japan
o Australia
o Rest of Asia-Pacific

  • Middle East and Africa


Key Developments

  • In June 2023, Biogen Inc. launched a new SPINRAZA (nusinersen) data strived to answer critical questions for the spinal muscular atrophy (SMA) community. The data were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA.
  • In October 2022, Axoft, a neurotechnology corporation, introduced and obtained the FDA Breakthrough Device designation for its brain-machine interface (BMI) to better treat neurological disorders.
  • In October 2022, SpineX, Inc., a clinical-stage medtech corporation reported the groundbreaking results of its first in-human study in children with cerebral palsy.
  • In January 2021, Theranica, a prescribed digital therapeutics (PDT) corporation obtained the Food and Drug Administration clearance to market its Nerivio therapeutic device for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older.



Competitive Landscape
The major global players in the market include Abbott Laboratories, LivaNova PLC, Medtronic PLC, Natus Medical Inc., Stryker Corporation, B.Barun SE, Integra Lifesciences Corporation, Boston Scientific Corporation, Zimmer Biomet and NeuroSigma, Inc. among others.
Why Purchase the Report?

  • To visualize the global pediatric neurology devices market segmentation based on product type, indication, age group, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of pediatric neurology devices market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.


The global pediatric neurology devices market report would provide approximately 69 tables, 73 figures and 194 pages.
Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies